search
Back to results

A Study to Evaluate the Pharmacokinetics of HSK7653 in Subjects With Renal Impairment

Primary Purpose

Renal Impairment

Status
Completed
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
HSK7653 tablets
Sponsored by
Haisco Pharmaceutical Group Co., Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Renal Impairment

Eligibility Criteria

18 Years - 79 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

Subjects with renal impairment(RI):

  1. Voluntarily sign the informed consent form, understand the trial procedures, and be willing to comply with all trial procedures and restrictions;
  2. 18 years to 79 years (inclusive), male and female;
  3. Male subjects weight ≥50 kg and female subjects weight ≥45 kg. Body mass index (BMI) : 18-30 kg/m2 (inclusive) (BMI= weight (kg)/height2 (m^2));
  4. Subjects with medically stable RI until study completion corresponding to the Classifications of Renal Function based on GFR: mild RI: 60≤GFR<90 mL/min; moderate RI: 30≤GFR<60 mL/min, severe RI:15≤GFR<30 mL/min, kidney failure:GFR<15 mL/min (not on hemodialysis);
  5. Physical examination, vital sign measurements, 12-lead electrocardiogram (ECG), and clinical laboratory tests (hematology, serum chemistry, coagulation and urinalysis test) results were deemed appropriate by the investigator;
  6. Not in use of any drug within 2 weeks prior to screening, except for the medication necessary for RI/ other comorbidities (last more than four weeks in good compliance);
  7. Subjects (including partners) are willing to voluntarily use effective contraceptives from screening to at least 6 months after the last dose administration;

Subjects with normal renal function :

  1. Voluntarily sign the informed consent form, understand the trial procedures, and be willing to comply with all trial procedures and restrictions;
  2. 18 years to 79 years (inclusive), male and female, age and sex must be matched with subjects with RI;
  3. Male subjects weight ≥50 kg and female subjects weight ≥45 kg, weight must be matched with subjects with RI. Body mass index (BMI) : 18-30 kg/m^2 (inclusive) (BMI= weight (kg)/height2 (m^2));
  4. 90≤GFR<130 mL/min;
  5. Physical examination, vital sign measurements, 12-lead electrocardiogram (ECG), and clinical laboratory tests (hematology, serum chemistry, coagulation and urinalysis test) results were deemed appropriate by the investigator;
  6. Not in use of any drug within 2 weeks prior to screening, except for the medication necessary for comorbidities (last more than four weeks in good compliance);
  7. Subjects (including partners) are willing to voluntarily use effective contraceptives from screening to at least 6 months after the last dose administration;

Exclusion Criteria:

  1. Subjects who have a allergic history of DPP4 inhibitors or have a history of allergy to the test drug and the related compounds;
  2. Have a history of severe and uncontrolled diseases, such as cardiovascular, respiratory, liver, gastrointestinal, endocrine, hematologic, mental/nervous systems diseases within one year prior to screening;
  3. History or clinical evidence of acute or chronic pancreatitis, or clinically significant abnormalities in blood lipase and/or blood amylase results at screening;
  4. Have conditions that may affect drug absorption, distribution, metabolism, or excretion (e.g., disease, drugs or surgery);
  5. Use of any DPP-IV enzyme inhibitor within 2 weeks prior to the screening;
  6. Experienced severe hypoglycemia within 3 months before screening;
  7. Acute renal failure;
  8. Smoking more than 5 cigarettes per day within 3 months prior to screening or smoking during the study;
  9. Average alcohol intake is more than 14 unit per week (1unit=17.7 mL alcohol , 1 unit=357mL 5% alcohol beer, or 43mL 40% alcohol spirit, or 147mL 12% alcohol wine) within the 3 months prior to screening, or taking any alcohol during study or a positive ethanol breath test at screening;
  10. Drug abuse history within 5 years prior to screening, or positive urine drug screen at screening;
  11. History of high consumption of grapefruit juice, methylxanthine-rich food or beverage (such as coffee, tea, cola, chocolate, energy drinks) , consumption of grapefruit juice, methylxanthine-rich food within 48 hours before the administration ;
  12. Participation in another clinical trial within 3 months before screening;
  13. Blood donation (or blood loss) ≥400 mL, or receiving blood products to improve anemia within 3 months prior to the screening;
  14. Aspartate aminotransferase (AST), alanine aminotransferase (ALT) > 2 × upper limit of normal, or bilirubin > 1.5 × upper limit of normal;
  15. Have a positive result for hepatitis B surface antigen, hepatitis C virus antibody, human immunodeficiency virus antibody, or anti-treponema pallidum specific antibody;
  16. A pregnant/lactating woman, or has a positive pregnancy test at screening or during the trial;
  17. Not suitable for this study as judged by the investigator.

Sites / Locations

  • Beijing Jishuitan Hospital

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm Type

Experimental

Experimental

Experimental

Experimental

Experimental

Arm Label

Mild Renal Impairment

Moderate Renal Impairment

Severe Renal Impairment

Kidney failure

Normal Renal function

Arm Description

A1 group subjects will receive a single dose of 10 mg HSK7653

B1 group subjects will receive a single dose of 10 mg HSK7653

C1 group subjects will receive a single dose of 10 mg HSK7653

D1 group subjects will receive a single dose of 10 mg HSK7653

A2, B2, C2 and D2 group subjects will receive a single dose of 10 mg HSK7653, If the age, sex and weight of the subjects in group A2 can be matched with the subjects in groups A1 and B1 at the same time, the subjects in group B2 will not be enrolled, and so on.

Outcomes

Primary Outcome Measures

Cmax
The pharmacokinetic parameters of HSK7653 in plasma
AUC0-t
The pharmacokinetic parameters of HSK7653 in plasma
AUC0-inf
The pharmacokinetic parameters of HSK7653 in plasma

Secondary Outcome Measures

Tmax
The pharmacokinetic parameters of HSK7653 in plasma
t1/2
The pharmacokinetic parameters of HSK7653 in plasma
Vz/F
The pharmacokinetic parameters of HSK7653 in plasma
CL/F
The pharmacokinetic parameters of HSK7653 in plasma
Ae
The pharmacokinetic parameters of HSK7653 in urine
Fe
The pharmacokinetic parameters of HSK7653 in urine
CLr
The pharmacokinetic parameters of HSK7653 in urine
DPP4 inhibition AUEC
The pharmacodynamic parameters of HSK7653 in plasma
DPP4 inhibition Emax
The pharmacodynamic parameters of HSK7653 in plasma
DPP4 inhibition E336h
The pharmacodynamic parameters of HSK7653 in plasma
The number of volunteers with adverse events as a measure of safety
The number of volunteers with adverse events as a measure of safety

Full Information

First Posted
August 9, 2022
Last Updated
December 30, 2022
Sponsor
Haisco Pharmaceutical Group Co., Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT05497297
Brief Title
A Study to Evaluate the Pharmacokinetics of HSK7653 in Subjects With Renal Impairment
Official Title
An Open-label, Single-dose Study to Assess the Pharmacokinetics of HSK7653 Tablets in Subjects With Varying Degrees of Renal Impairment Compared to the Control Subjects With Normal Renal Function
Study Type
Interventional

2. Study Status

Record Verification Date
August 2022
Overall Recruitment Status
Completed
Study Start Date
August 4, 2022 (Actual)
Primary Completion Date
October 23, 2022 (Actual)
Study Completion Date
October 26, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Haisco Pharmaceutical Group Co., Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This is an open-label, single-dose study to evaluate the pharmacokinetics, pharmacodynamics and safety of HSK7653 in subjects with mild, moderate, severe renal impairment and subjects with kidney failure compared to the matched control subjects with normal renal function.
Detailed Description
This is an open-label, single-dose Phase I study that evaluate the pharmacokinetics, pharmacodynamics and safety of a single dose of HSK7653 10 mg in subjects with mild, moderate, and severe renal impairment , subjects with kidney failure and the control subjects with normal renal function. This study consists of a screening period (Day -14 to Day -1), a baseline period (Day -1), a treatment period (Day 1 to Day 29), and a follow-up call on Day 32. Subjects will be enrolled in the following groups: Glomerular filtration rate (GFR, unit mL/min/1.73m^2) will be calculated based on Modification of Diet in Renal Disease (MDRD) equation at screening, Multiply it by BSA, then divide by 1.73 to convert to absolute GFR (unit, mL/min) (group A1) mild renal impairment (60 ≤ GFR< 90 mL/min); (group B1) moderate renal impairment (30 ≤ GFR<60 mL/min); (group C1) severe renal impairment (15 ≤ GFR< 30 mL/min); (group D1) kidney failure (<15 mL/min, not on hemodialysis); (group A2,B2,C2,D2) control subjects with normal renal function will be matched with subjects with renal impairment by weight, age, and sex (GFR≥90 mL/min).If subjects in group A2 can be matched with the subjects in groups A1 and B1 at the same time, the subjects in group B2 will not be enrolled, and so on. Approximately 64 subjects will be enrolled in total.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Renal Impairment

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
42 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Mild Renal Impairment
Arm Type
Experimental
Arm Description
A1 group subjects will receive a single dose of 10 mg HSK7653
Arm Title
Moderate Renal Impairment
Arm Type
Experimental
Arm Description
B1 group subjects will receive a single dose of 10 mg HSK7653
Arm Title
Severe Renal Impairment
Arm Type
Experimental
Arm Description
C1 group subjects will receive a single dose of 10 mg HSK7653
Arm Title
Kidney failure
Arm Type
Experimental
Arm Description
D1 group subjects will receive a single dose of 10 mg HSK7653
Arm Title
Normal Renal function
Arm Type
Experimental
Arm Description
A2, B2, C2 and D2 group subjects will receive a single dose of 10 mg HSK7653, If the age, sex and weight of the subjects in group A2 can be matched with the subjects in groups A1 and B1 at the same time, the subjects in group B2 will not be enrolled, and so on.
Intervention Type
Drug
Intervention Name(s)
HSK7653 tablets
Other Intervention Name(s)
HSK7653
Intervention Description
HSK7653, tablet, oral
Primary Outcome Measure Information:
Title
Cmax
Description
The pharmacokinetic parameters of HSK7653 in plasma
Time Frame
Predose and 0.25, 0.5, 1, 2, 4, 8 , 12, 24, 72, 168, 336, 504, 672 hours after dosing
Title
AUC0-t
Description
The pharmacokinetic parameters of HSK7653 in plasma
Time Frame
Predose and 0.25, 0.5, 1, 2, 4, 8 , 12, 24, 72, 168, 336, 504, 672 hours after dosing
Title
AUC0-inf
Description
The pharmacokinetic parameters of HSK7653 in plasma
Time Frame
Predose and 0.25, 0.5, 1, 2, 4, 8 , 12, 24, 72, 168, 336, 504, 672 hours after dosing
Secondary Outcome Measure Information:
Title
Tmax
Description
The pharmacokinetic parameters of HSK7653 in plasma
Time Frame
Predose and 0.25, 0.5, 1, 2, 4, 8 , 12, 24, 72, 168, 336, 504, 672 hours after dosing
Title
t1/2
Description
The pharmacokinetic parameters of HSK7653 in plasma
Time Frame
Predose and 0.25, 0.5, 1, 2, 4, 8 , 12, 24, 72, 168, 336, 504, 672 hours after dosing
Title
Vz/F
Description
The pharmacokinetic parameters of HSK7653 in plasma
Time Frame
Predose and 0.25, 0.5, 1, 2, 4, 8 , 12, 24, 72, 168, 336, 504, 672 hours after dosing
Title
CL/F
Description
The pharmacokinetic parameters of HSK7653 in plasma
Time Frame
Predose and 0.25, 0.5, 1, 2, 4, 8 , 12, 24, 72, 168, 336, 504, 672 hours after dosing
Title
Ae
Description
The pharmacokinetic parameters of HSK7653 in urine
Time Frame
Predose and 168 hours after dosing
Title
Fe
Description
The pharmacokinetic parameters of HSK7653 in urine
Time Frame
Predose and 168 hours after dosing
Title
CLr
Description
The pharmacokinetic parameters of HSK7653 in urine
Time Frame
Predose and 168 hours after dosing
Title
DPP4 inhibition AUEC
Description
The pharmacodynamic parameters of HSK7653 in plasma
Time Frame
Predose and 1, 24, 72, 168, 336 hours after dosing
Title
DPP4 inhibition Emax
Description
The pharmacodynamic parameters of HSK7653 in plasma
Time Frame
Predose and 1, 24, 72, 168, 336 hours after dosing
Title
DPP4 inhibition E336h
Description
The pharmacodynamic parameters of HSK7653 in plasma
Time Frame
Predose and 1, 24, 72, 168, 336 hours after dosing
Title
The number of volunteers with adverse events as a measure of safety
Description
The number of volunteers with adverse events as a measure of safety
Time Frame
Day 1 to Day 32

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
79 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Subjects with renal impairment(RI): Voluntarily sign the informed consent form, understand the trial procedures, and be willing to comply with all trial procedures and restrictions; 18 years to 79 years (inclusive), male and female; Male subjects weight ≥50 kg and female subjects weight ≥45 kg. Body mass index (BMI) : 18-30 kg/m2 (inclusive) (BMI= weight (kg)/height2 (m^2)); Subjects with medically stable RI until study completion corresponding to the Classifications of Renal Function based on GFR: mild RI: 60≤GFR<90 mL/min; moderate RI: 30≤GFR<60 mL/min, severe RI:15≤GFR<30 mL/min, kidney failure:GFR<15 mL/min (not on hemodialysis); Physical examination, vital sign measurements, 12-lead electrocardiogram (ECG), and clinical laboratory tests (hematology, serum chemistry, coagulation and urinalysis test) results were deemed appropriate by the investigator; Not in use of any drug within 2 weeks prior to screening, except for the medication necessary for RI/ other comorbidities (last more than four weeks in good compliance); Subjects (including partners) are willing to voluntarily use effective contraceptives from screening to at least 6 months after the last dose administration; Subjects with normal renal function : Voluntarily sign the informed consent form, understand the trial procedures, and be willing to comply with all trial procedures and restrictions; 18 years to 79 years (inclusive), male and female, age and sex must be matched with subjects with RI; Male subjects weight ≥50 kg and female subjects weight ≥45 kg, weight must be matched with subjects with RI. Body mass index (BMI) : 18-30 kg/m^2 (inclusive) (BMI= weight (kg)/height2 (m^2)); 90≤GFR<130 mL/min; Physical examination, vital sign measurements, 12-lead electrocardiogram (ECG), and clinical laboratory tests (hematology, serum chemistry, coagulation and urinalysis test) results were deemed appropriate by the investigator; Not in use of any drug within 2 weeks prior to screening, except for the medication necessary for comorbidities (last more than four weeks in good compliance); Subjects (including partners) are willing to voluntarily use effective contraceptives from screening to at least 6 months after the last dose administration; Exclusion Criteria: Subjects who have a allergic history of DPP4 inhibitors or have a history of allergy to the test drug and the related compounds; Have a history of severe and uncontrolled diseases, such as cardiovascular, respiratory, liver, gastrointestinal, endocrine, hematologic, mental/nervous systems diseases within one year prior to screening; History or clinical evidence of acute or chronic pancreatitis, or clinically significant abnormalities in blood lipase and/or blood amylase results at screening; Have conditions that may affect drug absorption, distribution, metabolism, or excretion (e.g., disease, drugs or surgery); Use of any DPP-IV enzyme inhibitor within 2 weeks prior to the screening; Experienced severe hypoglycemia within 3 months before screening; Acute renal failure; Smoking more than 5 cigarettes per day within 3 months prior to screening or smoking during the study; Average alcohol intake is more than 14 unit per week (1unit=17.7 mL alcohol , 1 unit=357mL 5% alcohol beer, or 43mL 40% alcohol spirit, or 147mL 12% alcohol wine) within the 3 months prior to screening, or taking any alcohol during study or a positive ethanol breath test at screening; Drug abuse history within 5 years prior to screening, or positive urine drug screen at screening; History of high consumption of grapefruit juice, methylxanthine-rich food or beverage (such as coffee, tea, cola, chocolate, energy drinks) , consumption of grapefruit juice, methylxanthine-rich food within 48 hours before the administration ; Participation in another clinical trial within 3 months before screening; Blood donation (or blood loss) ≥400 mL, or receiving blood products to improve anemia within 3 months prior to the screening; Aspartate aminotransferase (AST), alanine aminotransferase (ALT) > 2 × upper limit of normal, or bilirubin > 1.5 × upper limit of normal; Have a positive result for hepatitis B surface antigen, hepatitis C virus antibody, human immunodeficiency virus antibody, or anti-treponema pallidum specific antibody; A pregnant/lactating woman, or has a positive pregnancy test at screening or during the trial; Not suitable for this study as judged by the investigator.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Wang Meixia
Organizational Affiliation
Beijing Jishuitan Hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Zhang dongliang
Organizational Affiliation
Beijing Jishuitan Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Beijing Jishuitan Hospital
City
Beijing
Country
China

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

A Study to Evaluate the Pharmacokinetics of HSK7653 in Subjects With Renal Impairment

We'll reach out to this number within 24 hrs